プレスリリース
前のページへ戻る
 


News Release
May 17, 2017
Your Contact:
Karen Tiano   +49 6151 72 44461

Merck Develops Alternative CRISPR Genome Editing Method
  • New technology to improve genome editing, advance new possibilities for research
  • Creates method to rapidly deploy newly discovered bacterial CRISPR systems in disease-specific applications
  • Research published in prestigious journal, Nature Communications

Darmstadt, Germany, May 17, 2017 Merck, a leading science and technology company, has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.

This new technique, called “proxy-CRISPR,” provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. However, proxy-CRISPR provides a rapid and simple method to increase their usability without the laborious need to re-engineer native CRISPR proteins.

The company has filed several patent applications on the proxy-CRISPR technology. These patent applications directed to the proxy-CRISPR technology are just some of several CRISPR patent application filings made by the company since 2012.

“With more flexible and easy-to-use genome editing technologies, there is greater potential in research, bioprocessing and novel treatment modalities,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “As a leader in genome editing, Merck’s new technology is just one example of our commitment to solving challenges in the genome editing field, and we will continue to make CRISPR research a priority.”

Merck’s research on proxy-CRISPR, “Targeted Activation of Diverse CRISPR-Cas Systems for Mammalian Genome Editing via Proximal CRISPR Targeting,” was published in the April 7, 2017 edition of Nature Communications. The article explains how to make CRISPR more efficient, flexible and specific by opening up the genome for the cutting of DNA, giving researchers more editing options.

CRISPR genome editing technology is advancing treatment options for some of the toughest medical conditions faced today, including chronic illnesses and cancers for which there are limited or no treatment options. The applications of CRISPR are far ranging — from identifying genes associated with cancer to reversing mutations that cause blindness. CRISPR enables genome editing using an enzyme called Cas9 to cut DNA, but this has limited targeting abilities. This limitation led to Merck’s focus on proxy-CRISPR.

Merck has a 14-year history in the genome editing field, and was the first company to globally offer custom biomolecules for genome editing (TargeTron™ biomolecules and zinc finger nucleases), driving adoption of these techniques within the global research community. Merck was also the first to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing researchers to explore more questions about the root causes. Merck supports development gene- and cell-based therapeutics and manufactures viral vectors, as well. In 2016, the company launched a genome editing initiative aimed at advancing research in this area through a dedicated team and enhanced resources, further solidifying the company’s commitment to this field.

The new technology is a follow-on to Merck’s existing CRISPR applications. The company’s next suite of genome editing tools for the research community, to be launched later in 2017, will include novel and modified versions of Cas and Cas-like proteins.

Merck’s CRISPR Epigenetic Activator (p300-Cas9), which advances the way scientists explore epigenetic modification and associated diseases, was recognized as one of the Top 10 Innovations by The Scientist in 2015.

メルクについて
Merck(メルク)はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。